Key Points
- Director Bernd Seizinger purchased 100,000 shares of Oncolytics on January 16 at an average of $1.04 per share (total $104,000), increasing his direct ownership to 466,991 shares — a 27.25% rise, per the SEC filing.
- Oncolytics (NASDAQ:ONCY) trades around $0.99 with a market cap of about $105M and a 12‑month range of $0.33–$1.51; the company slightly beat recent quarterly EPS estimates and carries a MarketBeat consensus rating of “Moderate Buy” with a $6.25 target amid mixed analyst opinions.
Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director Bernd Seizinger acquired 100,000 shares of the firm's stock in a transaction that occurred on Friday, January 16th. The stock was acquired at an average price of $1.04 per share, for a total transaction of $104,000.00. Following the completion of the transaction, the director directly owned 466,991 shares in the company, valued at approximately $485,670.64. This represents a 27.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Oncolytics Biotech Trading Down 2.0%
NASDAQ:ONCY opened at $0.99 on Wednesday. The company has a market capitalization of $105.09 million, a P/E ratio of -3.54 and a beta of 0.97. The firm has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $1.09. Oncolytics Biotech Inc. has a twelve month low of $0.33 and a twelve month high of $1.51.
Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. On average, equities research analysts predict that Oncolytics Biotech Inc. will post -0.28 earnings per share for the current year.
Analyst Upgrades and Downgrades
ONCY has been the subject of a number of analyst reports. Zacks Research raised Oncolytics Biotech from a "hold" rating to a "strong-buy" rating in a report on Friday, October 17th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. Wall Street Zen lowered shares of Oncolytics Biotech from a "hold" rating to a "sell" rating in a report on Saturday, November 15th. Finally, HC Wainwright raised their price target on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.25.
View Our Latest Research Report on ONCY
Hedge Funds Weigh In On Oncolytics Biotech
Several institutional investors have recently added to or reduced their stakes in the business. Scientech Research LLC purchased a new position in Oncolytics Biotech during the third quarter worth about $25,000. Seeds Investor LLC increased its stake in shares of Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company's stock valued at $173,000 after acquiring an additional 33,826 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Oncolytics Biotech during the 3rd quarter valued at about $535,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company's lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.
Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
